Relenza Rotadisk

Relenza Rotadisk Uses, Dosage, Side Effects, Food Interaction and all others data.

A guanido-neuraminic acid that is used to inhibit neuraminidase.

Relenza Rotadisk, an antiviral agent, is a neuraminidase inhibitor indicated for treatment of uncomplicated acute illness due to influenza A and B virus in adults and pediatric patients 7 years and older who have been symptomatic for no more than 2 days. Relenza Rotadisk has also been shown to significantly inhibit the human sialidases NEU3 and NEU2 in the micromolar range (Ki 3.7 +/-0.48 and 12.9+/-0.07 microM, respectively), which could account for some of the rare side effects of zanamivir.

Table Of contents

• Relenza Rotadisk
• Uses
• Dosage
• Side Effect
• Precautions
• Interactions
• Uses during Pregnancy
• Uses during Breastfeeding
• Accute Overdose
• Food Interaction
• Half Life
• Volume of Distribution
• Clearance
• Interaction With other Medicine
• Contradiction
• Storage

Trade Name	Relenza Rotadisk
Availability	Prescription only
Generic	Zanamivir
Zanamivir Other Names	Zanamivir
Related Drugs	amantadine, Tamiflu, oseltamivir, Fluzone, Vicks DayQuil Severe Cold & Flu, Xofluza, Coricidin HBP Cold & Flu, Afluria, Fluad, Relenza
Weight	5mg
Type	Inhaler
Formula	C12H20N4O7
Weight	Average: 332.3098 Monoisotopic: 332.133199014
Protein binding	Zanamivir has limited plasma protein binding (<10%).
Groups	Approved, Investigational
Therapeutic Class
Manufacturer	Glaxosmithkline
Available Country	Pakistan
Last Updated:	September 19, 2023 at 7:00 am

Uses

Relenza Rotadisk is a neuraminidase inhibitor used to treat influenza A and B.

For the prevention and treatment of influenza A and B.

Relenza Rotadisk is also used to associated treatment for these conditions: Flu caused by Influenza

How Relenza Rotadisk works

The proposed mechanism of action of zanamivir is via inhibition of influenza virus neuraminidase with the possibility of alteration of virus particle aggregation and release. By binding and inhibiting the neuraminidase protein, the drug renders the influenza virus unable to escape its host cell and infect others.

Food Interaction

No interactions found.

Relenza Rotadisk Disease Interaction

Major: asthma/COPD

Elimination Route

Absolute bioavailability is very low following oral administration (2%). Following oral inhalation, bioavailability is 4% to 17%.

Half Life

2.5-5.1 hours

Clearance

• 2.5 - 10.9 L/h [Following oral inhalation 10 mg]
• 5.3 L/h [Normal renal function receiving IV single dose of 4 mg or 2 mg]
• 2.7 L/h [Patients with mild and moderate renal impairement receiving IV single dose of 4 mg or 2 mg]
• 0.8 L/h [Patients with severe renal impairement receiving IV single dose of 4 mg or 2 mg]

Elimination Route

It is excreted unchanged in the urine with excretion of a single dose completed within 24 hours. Unabsorbed drug is excreted in the feces.Relenza Rotadisk is renally excreted as unchanged drug.

Innovators Monograph

You find simplified version here Relenza Rotadisk